You are about to leave the Clinical Value website now.


APASL 2022 Seoul

The liver cancer landscape has been undergoing a period of rapid transformation. From early detection of HCC using new biomarkers, to new immunotherapy treatment options. Watch the APASL 2022 webinars to hear experts share updates in the diagnosis and testing, and treatment of HCC.

Luncheon Symposium


Dr. Joong-Won Park

National Cancer Centre

Prof. Henry Chan

Deputy Chief Hospital Manager at Union Hospital in Hong Kong, and Honorary Clinical Professor of the Faculty of Medicine at The Chinese University of Hong Kong.

Prof. Masatoshi Kudo

Professor and Chairman of The Faculty of Medicine at Kindai University, Osaka, Japan

Role of PIVKA-II in HCC surveillance

The evolution of 1st line treatment: from evidence to practice


Industry Symposium


Prof. Do Young Kim

Professor of Department of Internal Medicine at Yonsei University College of Medicine

Prof. Su Jong Yu

Professor of Internal Medicine at Seoul National University College of Medicine, Korea.

Assoc. Prof. Wonseok Kang

Associate Professor at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Clinical usefulness of PIVKA-II in HCC diagnosis and treatment monitoring

Treating with confidence: Managing patients on Atezolizumab + Bevacizumab


This website contains information targeted at healthcare professionals and could contain information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for you accessing information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

Be the first to receive updates, event opportunities, and thought leadership insights.